- Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
- Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
- Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
- Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
- Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
- Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
- Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
- Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
- Can-Fite Reports 2022 Financial Results & Provides Clinical Update
- Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
More ▼
Key statistics
On Thursday, Can Fite Biopharma Ltd (CANF:TLV) closed at 3.30, 57.14% above the 52 week low of 2.10 set on May 02, 2023.
52-week range
Open | 3.30 |
---|---|
High | 3.40 |
Low | 3.20 |
Bid | 3.30 |
Offer | 3.40 |
Previous close | 3.40 |
Average volume | 7.81m |
---|---|
Shares outstanding | 1.22bn |
Free float | 815.32m |
P/E (TTM) | -- |
Market cap | 40.42m ILS |
EPS (TTM) | -0.0425 ILS |
Data delayed at least 20 minutes, as of Jun 08 2023 15:24 BST.
More ▼